White Willow Bark

White willow bark has been used for pain relief for over 3,500 years — Hippocrates prescribed chewing willow bark for fever and pain in 400 BCE. The bark contains salicin, the natural precursor to aspirin (acetylsalicylic acid), which was first synthesized from willow-derived salicylic acid by Bayer in 1897. Despite sharing a pharmacological ancestor, the whole bark extract works differently from aspirin.

Clinical trials have focused primarily on lower back pain and osteoarthritis, with a daily dose providing 240 mg of salicin showing consistent analgesic benefits. Unlike synthetic aspirin, willow bark is gentler on the stomach because salicin is converted to salicylic acid only after absorption in the gut and liver, bypassing direct gastric irritation. The bark also contains polyphenols and flavonoids that contribute additional anti-inflammatory effects not found in isolated aspirin.

Salicin, the primary active glycoside, is a prodrug that passes through the stomach intact and is hydrolyzed by intestinal flora and liver enzymes into salicylic acid, the same active metabolite produced by aspirin. However, salicylic acid is a weaker inhibitor of COX-1 and COX-2 than acetylsalicylic acid, which means less platelet inhibition and less gastric damage — but also less acute anti-inflammatory potency than high-dose aspirin.

The analgesic effect of whole willow bark extract cannot be explained by salicin content alone. Polyphenols, flavonoids, and other salicylates in the bark contribute synergistic anti-inflammatory and antioxidant activity. These compounds inhibit NF-kB activation, reduce TNF-alpha and interleukin production, and decrease COX-2 gene expression. This multi-compound synergy produces a slower onset but longer-duration pain relief compared to aspirin, with a more favorable gastrointestinal safety profile.